Denis Chem Lab Limited has reappointed Dr. Himanshu C. Patel as its Managing Director for a term of three years, effective August 1, 2026. The Board of Directors approved the reappointment during its meeting on July 29, 2026, based on the recommendation of the Nomination and Remuneration Committee. This leadership continuity ensures stability for the parenteral products manufacturer, with the appointment subject to final shareholder approval at the company’s 45th Annual General Meeting (AGM). Dr. Patel, who holds B.E., M.S., and Ph.D. qualifications, brings over four decades of experience in the medical and pharmaceutical sectors to the role.

The reappointment follows the expiration of Dr. Patel’s previous term on July 31, 2026. In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company disclosed that Dr. Himanshu C. Patel is related to Ms. Anar H. Patel and Mr. Dinesh B. Patel, both of whom are also directors on the Board. No other relationships between directors were reported in connection with this appointment. The company affirmed that Dr. Patel is not debarred from holding the office of director by virtue of any SEBI order or other regulatory authority.

Key Governance Details

Alongside the MD reappointment, the Board fixed September 18, 2026, as the record date for determining shareholders entitled to receive the final dividend for FY25-26, if declared at the AGM. The 45th AGM will be convened on September 25, 2026, at 12:00 p.m. IST via Video Conferencing or Other Audio Visual Means. Shareholders holding units on the record date will be eligible for dividend payments, which will be disbursed on or after September 25, 2026.

In accordance with Regulation 42 of the SEBI Listing Regulations, remote e-voting will commence at 9:00 a.m. on September 22, 2026, and conclude at 5:00 p.m. on September 24, 2026. The cut-off date for determining voting rights is September 18, 2026. E-voting during the AGM itself will remain active for 15 minutes after the conclusion of the meeting.

Leadership Profile

Dr. Himanshu C. Patel’s reappointment underscores his long-standing contribution to the company. He currently holds 2,048,137 equity shares in Denis Chem Lab Limited. His extensive background in industrial management within the pharmaceutical field aligns with the company’s focus on manufacturing parenteral products. The Nomination and Remuneration Committee’s recommendation highlights his strategic value to the organization’s ongoing operations and governance framework.

What This Means for Shareholders

Shareholders must ensure their holdings are registered on September 18, 2026, to qualify for the final dividend. Those wishing to vote on the MD reappointment and other resolutions must cast their ballots remotely between September 22 and September 24, 2026. The continuity of Dr. Patel’s leadership aims to provide strategic direction and operational stability for the next three years.

Denis Chem Lab reported a net profit of ₹840.93 lakh for the financial year ended March 31, 2026, marking a 4.1% increase from ₹807.58 lakh in the prior year. Revenue from operations grew 4.9% to ₹18,172.04 lakh from ₹17,329.97 lakh in FY25, supported by improved operational performance. The board has recommended a final dividend of ₹2.50 per equity share of ₹10 each for FY26, pending approval at the upcoming Annual General Meeting.

For the quarter ended March 31, 2026, the company recorded a net profit of ₹40.01 lakh, a decline from ₹70.75 lakh in the corresponding period of the previous year. Quarterly revenue from operations stood at ₹4,675.49 lakh, compared to ₹4,138.34 lakh in Q4FY25. Total expenses for the quarter increased to ₹4,615.11 lakh from ₹4,128.95 lakh, primarily due to higher material and employee costs.

The board, in its meeting on May 30, 2026, approved the standalone audited financial results. M/s. Shah & Shah Associates, Chartered Accountants, issued an unmodified opinion on the audited financial results. The company also appointed M/s. Kashyap R. Mehta & Partners as Secretarial Auditors to fill a casual vacancy and M/s. Kiran J. Mehta & Co. as Cost Auditors for FY 2026-27.

Financial Performance

The company’s earnings per share (EPS) for the full year improved to ₹6.06 from ₹5.82 in the previous year. Total comprehensive income for FY26 rose to ₹855.06 lakh from ₹820.69 lakh. The finance costs for the year increased to ₹84.07 lakh from ₹51.04 lakh, while depreciation and amortization expenses remained stable at ₹683.55 lakh.

Assets and Liabilities

As of March 31, 2026, the company’s total assets stood at ₹12,482.62 lakh, up from ₹11,227.24 lakh in the previous year. Total equity increased to ₹9,157.33 lakh from ₹8,510.42 lakh. Current liabilities rose to ₹3,166.61 lakh from ₹2,617.25 lakh, largely due to an increase in trade payables and current borrowings.

Cash Flow Statement

Net cash generated from operating activities for FY26 was ₹413.15 lakh, a decrease from ₹1,209.19 lakh in the previous year. Cash used in investing activities was ₹496.50 lakh, while financing activities generated ₹44.20 lakh. Cash and cash equivalents at the end of the year stood at ₹45.88 lakh, down from ₹85.03 lakh at the end of FY25.